Zoetis Inc. (NYSE:ZTS) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday, September 12th.
A number of other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Hilliard Lyons started coverage on Zoetis in a report on Tuesday, June 20th. They set a “buy” rating and a $77.00 target price on the stock. Deutsche Bank AG reissued a “buy” rating and set a $65.00 target price (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Argus reissued a “buy” rating and set a $69.00 target price (up previously from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $65.44.
Shares of Zoetis (ZTS) opened at 64.16 on Tuesday. Zoetis has a 12-month low of $46.86 and a 12-month high of $65.83. The company has a 50 day moving average price of $62.44 and a 200-day moving average price of $59.64. The firm has a market cap of $31.38 billion, a PE ratio of 36.27 and a beta of 1.02.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.49 earnings per share. Analysts expect that Zoetis will post $2.34 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its position in Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares in the last quarter. Harfst & Associates Inc. grew its position in Zoetis by 16.1% during the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares in the last quarter. Guardian Life Insurance Co. of America grew its position in Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after purchasing an additional 13 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in Zoetis during the 2nd quarter worth approximately $119,000. Finally, Assetmark Inc. grew its position in Zoetis by 4.6% during the 1st quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after purchasing an additional 85 shares in the last quarter. 93.20% of the stock is currently owned by institutional investors.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.